PISGAH FOREST, N.C., Dec. 7, 2012 /PRNewswire/ -- Pisgah Laboratories, Inc., an innovative intellectual property and drug development company located in Western North Carolina, was recently recognized for their technical achievements to reduce the Nation's drug abuse crisis. The Center for Lawful Access and Abuse Deterrence (CLAAD) sponsored the Top 5 Technologies Award contest to provide companies an opportunity to showcase their approach to drug abuse deterrence. The findings by the independent panel of contest judges placed Pisgah's technology platform into the selected Top 5.
The contest's sponsor, CLAAD, is a national non-profit coalition focused on the prevention of the misuse, abuse and diversion of prescription pharmaceutical products. As its name suggests, the organization simultaneously advocates legitimate patient access to such medications. The contest was established to increase public awareness and support the pharmaceutical industry's effort to scientifically address the immense drug abuse problem. The public announcement of Pisgah's standing in the contest was announced at CLAAD's November 27th, 2012 National Prescription Drug Abuse Prevention Strategy meeting in Washington, D.C.
Numerous patent allowances and product development updates have been reported over the past year that describe Pisgah's first flagship product, an abuse deterrent form of hydrocodone. Now, the technical recognition by CLAAD is a notable crown to Pisgah's achievements, but the company is also rapidly developing their marketing and branding strategy. In order to brand and support their technology platform, Pisgah has launched P2P INTERVENTIONS, www.P2PINTERVENTIONS.com. Ultimately, the technology website may serve as a resource and provide access by the public, and the medical community, to patent information on the abuse deterrent features available through Pisgah's innovations.
Clearly, this integrated approach of technical accomplishment to meet market needs and addressing the multitude of related business issues in advance of a launch has made Pisgah attractive to potential marketing partners. According to Todd Stamps, who is responsible for promoting Pisgah's drug abuse deterrence business, "Pisgah is uniquely positioned to help fill empty product pipelines with a host of pain management products which are patent protected and offer performance enhancing benefits." He knowingly added, "What other market opportunity could combine both exceptional growth with a sustaining financial model?"
Besides filling empty pipelines, Pisgah's technology is quite applicable to extending existing brand life-cycles. Many well-known branded products have come under fierce generic competition which is rapidly eroding the brands' revenues. The brands' market value through name recognition may remain quite high during the sales decline, but the endpoint is obvious. Existing branded products may be enticed to offer an abuse-deterrent line extension to revitalize their brand and create a rising sales tide. As examples, a return to top-line growth could well be applicable to branded products such as Vicodin®, Oxycontin®, and other pain management drugs. In addition, the often abused AD(H)D drugs, Adderall® and Ritalin® could use a revamping to increase sales while providing an additional abuse deterrent benefit.
In the meantime, Pisgah continues to develop their platform on combined business, marketing and technical fronts to provide a solid foundation to selected branding and marketing partners. Currently, Pisgah is prosecuting a number of product brand names through the FDA and USPTO trademarking process in order to be ready for launch implementation. For those interested in joining Pisgah's program as a brand or marketing partner, please contact Mr. Stamps through the number below.
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE Pisgah Laboratories, Inc.